Pugsley A P, Zimmerman W, Wehrli W
Unité de Génétique Moléculaire, Institut Pasteur, Paris, France.
J Gen Microbiol. 1987 Dec;133(12):3505-11. doi: 10.1099/00221287-133-12-3505.
Rifamycin CGP 4832 is a semisynthetic rifamycin derivative. It is at least 200 times more active than rifampicin against Escherichia coli and related bacteria. This increased activity is shown here to be due to the efficient uptake of CGP 4832 across the E. coli outer membrane via the ferrichrome transport system comprising the outer membrane FhuA (TonA) protein, the ferrichrome receptor, and the inner membrane TonB protein. CGP 4832 competed with ferrichrome and other iron siderophore complexes, and with bacteriophage T5 and colicin M for binding sites on the FhuA protein. Mutations in fhuA or tonB genes reduce CGP 4832 sensitivity to a level comparable to that to rifampicin. There is no evidence that CGP 4832 or rifampicin utilize the inner membrane ferrichrome transport system to gain entry into the cytoplasm.
利福霉素CGP 4832是一种半合成利福霉素衍生物。它对大肠杆菌及相关细菌的活性比对利福平至少高200倍。此处表明这种活性增加是由于CGP 4832通过由外膜FhuA(TonA)蛋白、高铁色素受体和内膜TonB蛋白组成的高铁色素转运系统有效穿过大肠杆菌外膜所致。CGP 4832与高铁色素及其他铁载体复合物、噬菌体T5和大肠杆菌素M竞争FhuA蛋白上的结合位点。fhuA或tonB基因突变会将CGP 4832的敏感性降低到与利福平相当的水平。没有证据表明CGP 4832或利福平利用内膜高铁色素转运系统进入细胞质。